chartexchange

Who Is Paying For GeneDx’s Cash Burn?

Trefis | Nov 12, 2026 12:43 PM EST

For questions about this article or underlying research, email help@trefis.com. GeneDx Holdings Corp. (WGS) sells exome and genome tests ordered by clinicians for their patients. During fiscal Q3 2026, the quarter through September, the cash left after running the business and capital spending was a negative $15.8 million. The company burned cash in all four […]

Read original article